✦ LIBER ✦

TGF-α-Driven Tumor Growth Is Inhibited by an EGF Receptor Tyrosine Kinase Inhibitor

✍ Scribed by A. El-Obeid; G. Hesselager; B. Westermark; M. Nistér

Book ID: 115589250
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 476 KB
Volume: 290
Category: Article
ISSN: 0006-291X
DOI: 10.1006/bbrc.2001.6210

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Inhibition of transforming growth factor

Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868

✍ Simpson, B J B; Rabiasz, G; Gordge, P; Smyth, J; Langdon, S P 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 191 KB

Apoptosis and growth inhibition of head

Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor

✍ R.A. Faust; S. Tawfic; A.T. Davis; K. Ahmed 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 339 KB

Stimulation or inhibition of A431 cell g

Stimulation or inhibition of A431 cell growth by EGF is directly correlated with receptor tyrosine kinase concentration but not with PLCγ activity

✍ Jan-Kan Chen; Song-Shu Lin 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 472 KB

36 Improved Inhibition of Tumor Growth b

36 Improved Inhibition of Tumor Growth by the Novel Monoclonal Antibody VGX-100 Targeting VEGF-C in Combination with VEGF-Receptor Tyrosine Kinase Inhibitors

✍ Tester, A.; Phelan, D.; Gerometta, M.; Klupacs, R.; Baldwin, M.E. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant